scholarly journals Construct validity of the Clinical Dementia Rating Scale to assess the level of cognitive decline by informants

2021 ◽  
Vol 17 (S6) ◽  
Author(s):  
Renata Eloah de Lucena Ferretti‐Rebustini ◽  
Flávio Rebustini ◽  
Claudia K. Suemoto ◽  
Lea T. Grinberg ◽  
Renata Elaine P. Leite ◽  
...  
2020 ◽  
pp. 089198872094423
Author(s):  
Thaís Bento Lima-Silva ◽  
Eneida Mioshi ◽  
Valéria Santoro Bahia ◽  
Mário Amore Cecchini ◽  
Luciana Cassimiro ◽  
...  

Introduction: There is a shortage of validated instruments to estimate disease progression in frontotemporal dementia (FTD). Objectives: To evaluate the ability of the FTD Rating Scale (FTD-FRS) to detect functional and behavioral changes in patients diagnosed with the behavioral variant of FTD (bvFTD), primary progressive aphasia (PPA), and Alzheimer disease (AD) after 12 months of the initial evaluation, compared to the Clinical Dementia Rating scale−frontotemporal lobar degeneration (CDR-FTLD) and the original Clinical Dementia Rating scale (CDR). Methods: The sample consisted of 70 individuals, aged 40+ years, with at least 2 years of schooling, 31 with the diagnosis of bvFTD, 12 with PPA (8 with semantic variant and 4 with non-fluent variant), and 27 with AD. The FTD-FRS, the CDR, and the 2 additional CDR-FTLD items were completed by a clinician, based on the information provided by the caregiver with frequent contact with the patient. The Addenbrooke Cognitive Examination-Revised was completed by patients. After 12 months, the same protocol was applied. Results: The FTD-FRS, CDR-FTLD, and CDR detected significant decline after 12 months in the 3 clinical groups (exception: FTD-FRS for PPA). The CDR was less sensitive to severe disease stages. Conclusions: The FTD-FRS and the CDR-FTLD are especially useful tools for dementia staging in AD and in the FTD spectrum.


2009 ◽  
Vol 5 (4S_Part_10) ◽  
pp. P292-P292 ◽  
Author(s):  
Hee Jin Kang ◽  
Young-Hee Chang ◽  
Ha-Ry Na ◽  
Min Jae Baek ◽  
Hyun Jung Kim ◽  
...  

2003 ◽  
Vol 17 (2) ◽  
pp. 98-105 ◽  
Author(s):  
Seong Hye Choi ◽  
Byung Hwa Lee ◽  
Seonwoo Kim ◽  
Dong Seok Hahm ◽  
Jee Hyang Jeong ◽  
...  

2016 ◽  
Vol 7 (2) ◽  
pp. 57-62
Author(s):  
Maria L Chuhlovina ◽  
Denis V Zaslavsky ◽  
Ekaterina A Bichun

The research objective is investigation of clinical manifestations of neurosyphilis in women of reproductive age. The diagnoses were based on complaints, anamnestic information, neurological examinations, dermatovenerology consultations, serological blood and liquor tests. All the patients underwent psychometric tests. The following methods were used: mini-mental state examination (MMSE), “Frontal Assessment Battery”, Clinical Dementia Rating scale, Clock drawing test, “Information-Memory-Consideration Concentration” test, Mattis Dementia Rating Scale. Nine patients with early neurosyphilis (between the ages of 18 to 40) and eight patients with late neurosyphilis (between the ages of 28 to 43) were surveyed. Syphilitic meningitis (six cases), meningovascular neurosyphilis (three cases) were found in patients with early neurosyphilis. As for the patients with late neurosyphilis, two of them were diagnosed to have syphilitic meningitis, two patients had meningovascular neurosyphilis, two had progressive paralysis, tabes dorsalis was identified in one patient, one had taboparalysis. Only three patients showed specific skin and mucic manifestations. The patients at all the stages of neurosyphilis demonstrated mild cognitive impairments. Moderate dementia was found in one patient with early meningovascular neurosyphilis and one patient with progressive paralysis. This article considers a clinical case of a female patient with early syphilitic meningitis who had a baby with congenital syphilis.


2011 ◽  
Vol 24 (2) ◽  
pp. 197-204 ◽  
Author(s):  
Alessandro Sona ◽  
Ping Zhang ◽  
David Ames ◽  
Ashley I. Bush ◽  
Nicola T. Lautenschlager ◽  
...  

ABSTRACTBackground: The AIBL study, which commenced in November 2006, is a two-center prospective study of a cohort of 1112 volunteers aged 60+. The cohort includes 211 patients meeting NINCDS-ADRDA criteria for Alzheimer's disease (AD) (180 probable and 31 possible). We aimed to identify factors associated with rapid cognitive decline over 18 months in this cohort of AD patients.Methods: We defined rapid cognitive decline as a drop of 6 points or more on the Mini-Mental State Examination (MMSE) between baseline and 18-month follow-up. Analyses were also conducted with a threshold of 4, 5, 7 and 8 points, as well as with and without subjects who had died or were too severely affected to be interviewed at 18 months and after, both including and excluding subjects whose AD diagnosis was “possible” AD. We sought correlations between rapid cognitive decline and demographic, clinical and biological variables.Results: Of the 211 AD patients recruited at baseline, we had available data for 156 (73.9%) patients at 18 months. Fifty-one patients were considered rapid cognitive decliners (32.7%). A higher Clinical Dementia Rating scale (CDR) and higher CDR “sum of boxes” score at baseline were the major predictors of rapid cognitive decline in this population. Furthermore, using logistic regression model analysis, patients treated with a cholinesterase inhibitor (CheI) had a higher risk of being rapid cognitive decliners, as did males and those of younger age.Conclusions: Almost one third of patients satisfying established research criteria for AD experienced rapid cognitive decline. Worse baseline functional and cognitive status and treatment with a CheI were the major factors associated with rapid cognitive decline over 18 months in this population.


Sign in / Sign up

Export Citation Format

Share Document